476 (476 15)
Letrozole Tablet
Product Images NDC 50268-476
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 50268-476). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Letrozole 01)
Figure 1 (Letrozole 02)
This appears to be a table with some statistical data related to two different treatments, Letrozole and Tamoxifen. The data appears to show the number of patients in each treatment group, the number of events (presumably negative outcomes or side effects), and the number of patients who were censored (presumably lost to follow-up or withdrawn from the study). The table also seems to show the number of patients "at risk" over a period of 72 months. However, it is difficult to draw any specific conclusions without additional context or information.*
Figure 2 (Letrozole 03)
This is a data point indicating the number of months during which a specific medical condition, such as cancer, did not progress as determined by medical tests or imaging scans. It is unclear what specific medical condition or context this data point is referring to.*
Figure 3 (Letrozole 04)
Figure 4 (Letrozole 05)
Figure 5 (Letrozole 06)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
